drugset / Trial / NCT01354743
Upper Facial Remodeling With Perlane-L and Dysport
Phase 4
Completed
20 enrolled
Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide data to support combination treatment of the upper face with Perlane-L® and Dysport™. This study will assess the outcome of upper face rejuvenation in the temporal fossa; outcome of glabella and/or periorbital regions will also be assessed as a secondary endpoint.
Timeline
- Start
- 2010-12
- Primary completion
- 2011-12
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 0.25 ml | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 0.3 ml | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 0.35 ml | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 0.4 ml | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 20 unknown | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 30 unknown | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 50 unknown | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 60 unknown | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 70 unknown | — |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 80 unknown | — |
Indications
No indication recorded.